Clovis Oncology Inc (NASDAQ: CLVS) is a commercial stage biotechnology company engaged in developing and commercializing oncology treatments worldwide. The Company develops diagnostic tools through its partners, which can identify patients who will benefit the most from its developmental programs, focused on targeting specific subsets of cancer. The Company’s...
Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...
Aravive, Inc. (NASDAQ: ARAV), a clinical stage biotechnology Company engaged in developing therapeutics for solid tumours and hematologic malignancies, announced positive data from its ongoing Phase 1b/2 study of AVB-500, intended for treatment of Ovarian cancer patients. The results were presented at the European Society...
The American Cancer society estimates that in 2019, there will be around 22,530 new diagnoses of Ovarian Cancer and 13,980 women will succumb to the disease. It is the fifth largest cause for death in women, with over 1 in 78 chances of acquiring this...
